Selected Publications

Academic Article

Year Title Altmetric
2019 Allograft and patient survival after sequential HSCT and kidney transplantation from the same donor-A multicenter analysis.American Journal of Transplantation.  19:475-487. 2019
2018 Long-term follow-up of the DeKAF cross-sectional cohort study.American Journal of Transplantation2018
2018 Population Health, Ethnicity, and Rate of Living Donor Kidney Transplantation.Transplantation.  102:2080-2087. 2018
2018 Chronic dialysis in patients with end-stage renal disease: Relevance to kidney xenotransplantation.Xenotransplantation.  e12471. 2018
2018 Identification of genetic variants associated with tacrolimus metabolism in kidney transplant recipients by extreme phenotype sampling and next generation sequencing.Pharmacogenomics Journal2018
2018 Apolipoprotein L1 and Chronic Kidney Disease Risk in Young Potential Living Kidney Donors.Annals of Surgery.  267:1161-1168. 2018
2018 Expanding clarity or confusion? Volatility of the 5-tier ratings assessing quality of transplant centers in the United States.American Journal of Transplantation.  18:1494-1501. 2018
2018 Late graft failure after kidney transplantation as the consequence of late versus early events.American Journal of Transplantation.  18:1158-1167. 2018
2017 Xenotransplantation-the current status and prospects.British Medical Bulletin.  125:5-14. 2017
2017 Effect of Replacing Race With Apolipoprotein L1 Genotype in Calculation of Kidney Donor Risk Index.American Journal of Transplantation.  17:1540-1548. 2017
2017 Access to Kidney Transplantation among HIV-Infected Waitlist Candidates.Clinical Journal of the American Society of Nephrology.  12:467-475. 2017
2016 Obesity increases the risk of end-stage renal disease among living kidney donors.Kidney International.  91:699-703. 2016
2016 Cost-Effectiveness of Antibody-Based Induction Therapy in Deceased Donor Kidney Transplantation in the United States.Transplantation.  101:1234-1241. 2016
2016 APOL1 Genotype and Kidney Transplantation Outcomes From Deceased African American Donors.Transplantation.  100:194-202. 2016
2015 Moving Beyond Minimization Trials in Kidney Transplantation.Journal of the American Society of Nephrology.  26:2898-2901. 2015
2015 Medical management of chronic kidney disease in the renal transplant recipient.Current Opinion in Nephrology and Hypertension.  24:587-593. 2015
2015 Deceased donor multidrug resistance protein 1 and caveolin 1 gene variants may influence allograft survival in kidney transplantation.Kidney International.  88:584-592. 2015
2015 Apolipoprotein L1 gene variants in deceased organ donors are associated with renal allograft failure.American Journal of Transplantation.  15:1615-1622. 2015
2015 Reassessing medical risk in living kidney donors.Journal of the American Society of Nephrology.  26:1017-1019. 2015
2015 Identification of strategies to facilitate organ donation among African Americans using the nominal group technique.Clinical Journal of the American Society of Nephrology.  10:286-293. 2015
2015 Through a glass darkly: seeking clarity in preventing late kidney transplant failure.Journal of the American Society of Nephrology.  26:20-29. 2015
2014 The high cost of organ transplant commercialism.Kidney International.  86:858-859. 2014
2014 Kidney donors at increased risk? Additional studies are needed.Kidney International.  86:650. 2014
2014 Kidneys at higher risk of discard: expanding the role of dual kidney transplantation.American Journal of Transplantation.  14:404-415. 2014
2013 Future of Medicare immunosuppressive drug coverage for kidney transplant recipients in the United States.Clinical Journal of the American Society of Nephrology.  8:1258-1266. 2013
2012 Erratum: A realistic proposal-incentives may increase donation - We need trials now! (American Journal of Transplantation (2012) 12 (1957-1958) DOI:10.1111/j.1600-6143.2012.04117.x)American Journal of Transplantation.  12:2261. 2012
2012 Report of a consensus conference on transplant program quality and surveillance.American Journal of Transplantation.  12:1988-1996. 2012
2012 A realistic proposal--incentives may increase donation--we need trials now!American Journal of Transplantation.  12:1957-1958. 2012
2012 The APOL1 genotype of African American kidney transplant recipients does not impact 5-year allograft survival.American Journal of Transplantation.  12:1924-1928. 2012
2012 Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients.Transplantation.  93:1075-1085. 2012
2012 Counseling patients for kidney transplantation: awkward conversations?American Journal of Transplantation.  12:273-274. 2012
2011 Our evolving understanding of late kidney allograft failure.Current Opinion in Organ Transplantation.  16:594-599. 2011
2011 The PROMISE study: a phase 2b multicenter study of voclosporin (ISA247) versus tacrolimus in de novo kidney transplantation.American Journal of Transplantation.  11:2675-2684. 2011
2011 Prevention of cardiovascular disease in adult recipients of kidney transplants.Lancet.  378:1419-1427. 2011
2011 Therapeutic drug monitoring of mycophenolates in kidney transplantation: report of The Transplantation Society consensus meeting.Transplantation reviews.  25:58-64. 2011
2011 Advances in kidney transplant immunosuppression: Emerging biologicsDialysis and Transplantation.  40:30-32. 2011
2010 Living donor nephrectomy: understanding long-term risk in minority populations.American Journal of Transplantation.  10:2574-2576. 2010
2010 Inflammation in areas of tubular atrophy in kidney allograft biopsies: a potent predictor of allograft failure.American Journal of Transplantation.  10:2066-2073. 2010
2010 Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure.Transplantation.  90:68-74. 2010
2010 Optimizing medication adherence: an ongoing opportunity to improve outcomes after kidney transplantation.Clinical Journal of the American Society of Nephrology.  5:1305-1311. 2010
2010 Mycophenolic acid exposure in high- and low-weight renal transplant patients after dosing with mycophenolate mofetil in the Opticept trial.Therapeutic Drug Monitoring.  32:224-227. 2010
2010 Histopathologic clusters differentiate subgroups within the nonspecific diagnoses of CAN or CR: preliminary data from the DeKAF study.American Journal of Transplantation.  10:315-323. 2010
2010 Pathological and clinical characterization of the 'troubled transplant': data from the DeKAF study.American Journal of Transplantation.  10:324-330. 2010
2009 A Festschrift honoring Dr. John J. Curtis.Clinical Journal of the American Society of Nephrology.  4:2027-2028. 2009
2009 Chronic calcineurin inhibitor nephrotoxicity: reflections on an evolving paradigm.Clinical Journal of the American Society of Nephrology.  4:2029-2034. 2009
2009 Barriers to preemptive kidney transplantation.American Journal of Nursing.  109:28-37. 2009
2009 Use of cardioprotective medications in kidney transplant recipients.American Journal of Transplantation.  9:1811-1815. 2009
2009 Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial.American Journal of Transplantation.  9:1607-1619. 2009
2009 Transplant tourism and unregulated black-market trafficking of organs.American Journal of Transplantation.  9:1484. 2009
2009 Bortezomib successfully reduces monoclonal serum free light chain levels in a patient with recurrent myeloma and cast nephropathy in the renal transplant.Clinical Transplants.  439-441. 2009
2009 Must health literacy be a prerequisite for kidney transplantation?Clinical Journal of the American Society of Nephrology.  4:16-17. 2009
2008 Phase 1 dose-escalation study of CP-690 550 in stable renal allograft recipients: preliminary findings of safety, tolerability, effects on lymphocyte subsets and pharmacokinetics.American Journal of Transplantation.  8:1711-1718. 2008
2008 Transplant tourism: a modern iteration of an ancient problem.Current Opinion in Organ Transplantation.  13:395-399. 2008
2008 Systolic dysfunction portends increased mortality among those waiting for renal transplant.Journal of the American Society of Nephrology.  19:1191-1196. 2008
2008 Kidney transplantation as primary therapy for end-stage renal disease: a National Kidney Foundation/Kidney Disease Outcomes Quality Initiative (NKF/KDOQITM) conference.Clinical Journal of the American Society of Nephrology.  3:471-480. 2008
2007 The impact of left ventricular systolic dysfunction on survival after renal transplantation.Transplantation.  84:1610-1617. 2007
2007 Role of beta3 integrin in acute renal allograft rejection in humans.Clinical Journal of the American Society of Nephrology.  2:1268-1273. 2007
2007 Must all living donor compensation be viewed as valuable consideration? [2]American Journal of Transplantation.  7:1309-1310. 2007
2007 Racial disparities in renal allograft survival: a public health issue?Journal of The American College of Surgeons.  204:894-902. 2007
2006 Limiting financial disincentives in live organ donation: a rational solution to the kidney shortage.American Journal of Transplantation.  6:2548-2555. 2006
2006 The conspicuous costs of more of the same.American Journal of Transplantation.  6:1503-1504. 2006
2006 Current and evolving immunosuppressive regimens in kidney transplantation.American Journal of Kidney Diseases.  47:S3-21. 2006
2005 The relationship between ethnicity and outcomes in solid organ transplantation.Journal of Pediatrics.  147:721-723. 2005
2005 Improving access to renal transplantation.Seminars in Dialysis.  18:482-486. 2005
2005 Understanding the influence of ethnicity on renal allograft survival.American Journal of Transplantation.  5:2603-2604. 2005
2005 Mycophenolate mofetil: Ten years of clinical experience. IntroductionTransplantation.  80. 2005
2005 Association of CD20+ infiltrates with poorer clinical outcomes in acute cellular rejection of renal allografts.American Journal of Transplantation.  5:2248-2252. 2005
2005 Kidneys from deceased donors: maximizing the value of a scarce resource.American Journal of Transplantation.  5:1725-1730. 2005
2005 Long-term deterioration of kidney allograft function.American Journal of Transplantation.  5:1405-1414. 2005
2004 Transplantation in the diabetic patient with advanced chronic kidney disease: a task force report.American Journal of Kidney Diseases.  44:529-542. 2004
2004 "High-risk" renal transplantation: evolving definitions at a single center.Clinical Transplants.  121-126. 2004
2004 Whither living donors?American Journal of Transplantation.  4:2-3. 2004
2003 Equivalent pharmacokinetics of mycophenolate mofetil in African-American and Caucasian male and female stable renal allograft recipients.American Journal of Transplantation.  3:1581-1586. 2003
2003 Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation.Clinical Transplantation.  17:511-517. 2003
2003 The report of a national conference on the wait list for kidney transplantation.American Journal of Transplantation.  3:775-785. 2003
2003 Diabetes mellitus after kidney transplantation.American Journal of Transplantation.  3:512-513. 2003
2003 Determinants of cardiovascular mortality after renal transplantation: a role for cytomegalovirus?American Journal of Transplantation.  3:79-81. 2003
2002 The nondirected live-kidney donor: ethical considerations and practice guidelines: A National Conference Report.Transplantation.  74:582-589. 2002
2002 African Americans and renal transplantation: disproportionate need, limited access, and impaired outcomes.American Journal of the Medical Sciences.  323:94-99. 2002
2002 Addressing minority issues in renal transplantation: is more equitable access an achievable goal?American Journal of Transplantation.  2:1-3. 2002
2001 Evolution of immunosuppression and continued importance of acute rejection in renal transplantation.American Journal of Kidney Diseases.  38:S2-S9. 2001
2001 Maintenance immunosuppression in the renal transplant recipient: an overview.American Journal of Kidney Diseases.  38:S25-S35. 2001
2001 Noncomplication in solid organ transplantationCurrent Opinion in Organ Transplantation.  6:164-168. 2001
2001 Tolerance in renal transplantation after allogeneic bone marrow transplantation-6-year follow-up.Transplantation.  71:1681-1683. 2001
2000 Renal transplantation in black Americans.New England Journal of Medicine.  343:1545-1552. 2000
2000 Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation.Journal of the American Society of Nephrology.  11 Suppl 15:S1-86. 2000
2000 Prediction of renal transplant survival from early postoperative radioisotope studies.Journal of Nuclear Medicine.  41:1332-1336. 2000
2000 Postransplant lymphoproliferative disorder localized near the allograft in renal transplantation.Transplantation.  69:809-814. 2000
1999 Potential utility of rapamycin and tacrolimus in long-term, low-toxicity regimens.Transplantation Proceedings.  31:17S-22S. 1999
1999 Cytomegalovirus infections after treatment with daclizumab, an anti IL-2 receptor antibody, for prevention of renal allograft rejection. Roche Study Group.Transplantation.  68:310-313. 1999
1998 Development and clinical utility of daclizumab (Zenapax┬«), a humanized anti-Tac monoclonal antibody, in renal transplantationTodays Therapeutic Trends.  16:309-324. 1998
1998 Stumbling toward equity: The role of government in kidney transplantationUniversity of Illinois Law Review.  703. 1998
1998 Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation.Transplantation.  66:29-37. 1998
1998 Losartan, an angiotensin II type 1 receptor antagonist, lowers hematocrit in posttransplant erythrocytosis.Journal of the American Society of Nephrology.  9:1104-1108. 1998
1998 Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group.New England Journal of Medicine.  338:161-165. 1998
1998 Stumbling toward equity: the role of government in kidney transplantation.University of Illinois Law Review.  1998:703-725. 1998
1996 The evaluation of living renal transplant donors: clinical practice guidelines. Ad Hoc Clinical Practice Guidelines Subcommittee of the Patient Care and Education Committee of the American Society of Transplant Physicians.Journal of the American Society of Nephrology.  7:2288-2313. 1996
1996 Benefits of continued cyclosporine through an indigent drug program.American Journal of Kidney Diseases.  28:572-577. 1996
1996 Dilemmas in renal transplantation: when the clinical course and histological findings differ.American Journal of Kidney Diseases.  27:435-440. 1996
1996 Pentoxifylline does not prevent the cytokine-induced first dose reaction following OKT3--a randomized, double-blind placebo-controlled study.Transplantation.  61:573-577. 1996
1996 Impact of donor/recipient size matching on outcomes in renal transplantation.Transplantation.  61:383-388. 1996
1996 Factors affecting renal allograft survival in African Americans.Blood Purification.  14:327-333. 1996
1995 Evaluation of living renal donors. The current practice of US transplant centers.Transplantation.  60:322-327. 1995
1995 The evaluation of renal transplant candidates: clinical practice guidelines. Patient Care and Education Committee of the American Society of Transplant Physicians.Journal of the American Society of Nephrology.  6:1-34. 1995
1995 Progress in renal transplantation. A single center study of 3359 patients over 25 years.Annals of Surgery.  221:446-457. 1995
1995 HLA matching in renal transplantation.New England Journal of Medicine.  332:752-753. 1995
1995 Cyclosporine inhibits the renal response to L-arginine in human kidney transplant recipients.Journal of the American Society of Nephrology.  5:1426-1433. 1995
1994 Cytokines and transplantation: a clinical perspective.Transplantation science.  4 Suppl 1:S9-19. 1994
1994 Delayed graft function after renal transplantation: Causes, implications, and clinical managementJournal of Nephrology.  7:313-321. 1994
1994 Erythropoiesis after withdrawal of enalapril in post-transplant erythrocytosis.Kidney International.  46:1397-1403. 1994
1994 Posttransplant erythrocytosis: an enigma revisited.American Journal of Kidney Diseases.  24:1-11. 1994
1994 In ReplyJournal of the American Medical Association.  271:1403. 1994
1994 Race and Allocation of Kidneys for TransplantationJournal of the American Medical Association.  271:270-271. 1994
1994 Renal retransplantation: the role of race, quadruple immunosuppression, and the flow cytometry cross-match.Transplantation.  57:47-54. 1994
1993 Racial equity in renal transplantation. The disparate impact of HLA-based allocation.Journal of the American Medical Association.  270:1352-1356. 1993
1993 Experience with mycophenolate mofetil (RS61443) in renal transplantation at a single center.Annals of Surgery.  217:476-482. 1993
1993 Unequal racial access to kidney transplantation.Vanderbilt Law Review.  46:805-863. 1993
1993 Captopril-induced fall in glomerular filtration rate in cyclosporine-treated hypertensive patients.Journal of the American Society of Nephrology.  3:1570-1574. 1993
1993 Tapering or discontinuing cyclosporine for financial reasons--a single-center experience.American Journal of Kidney Diseases.  21:9-15. 1993
1992 Benefits of quadruple immunosuppressive therapy in recipients of living related donor kidneys. A review of 855 operations.Annals of Surgery.  215:606-616. 1992
1992 The impact of the UNOS mandatory sharing policy on recipients of the black and white races--experience at a single renal transplant center.Transplantation.  53:770-774. 1992
1992 Improved survival of primary cadaveric renal allografts in blacks with quadruple immunosuppression.Transplantation.  53:103-109. 1992
1991 Effects of enalapril on erythrocytosis after renal transplantation.Annals of Internal Medicine.  115:954-955. 1991
1991 Immunosuppression tailored to raceClinical Transplantation.  5:580-582. 1991
1991 Analysis of 22 years experience in living-related transplantation at the University of Alabama in Birmingham.Clinical Transplants.  179-191. 1991
1991 OKT3 first-dose reaction: association with T cell subsets and cytokine release.Kidney International.  39:141-148. 1991
1990 Donor antigen-specific immunosuppression in cadaveric and living-related donor kidney allograft recipients.Clinical Transplants.  289-300. 1990


Year Title Altmetric
2013 Mycophenolates.  250-266. 2013
2011 Immunosuppression: Past, present, and future.  19-30. 2011
2008 Hypertension in Renal Transplant Recipients.  675-679. 2008

Education And Training

  • Doctor of Medicine, Saint Louis University
  • Full Name

  • Robert Gaston
  • Blazerid

  • rgaston